



Updated Monthly

November 12, 2024

Prepared for:



THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

Published by:





## Questions?

Liz Powell, Esq., MPH

[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)

[www.G2Gconsulting.com](http://www.G2Gconsulting.com)

  @G2Gconsulting





# GBG Report

Updated Monthly

November 12, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

## TABLE OF CONTENTS

### New Opportunities

Aging.....	2
Artificial Intelligence & Machine Learning .....	3
Bioengineering.....	3
Biomedical Research.....	3
Blood Disorders.....	4
Cancer .....	4
Central Nervous System .....	9
Cognitive and Brain Health.....	10
Combat Casualty Care.....	11
Communication Disorders .....	12
Complementary and Integrative Health.....	12
Dental and Craniofacial Research .....	13
Diagnostics .....	13
Diversity and Inclusion.....	13
Energy Science .....	14
Environmental Health.....	14
Genomics .....	15
Health IT & Data.....	15
HIV/AIDS .....	16
Immunology & Infectious Disease .....	16
Lymphatic System.....	18
Maternal and Pediatric Health .....	18
Measurement Science .....	18
Medical Countermeasures.....	19

Mental Health.....	19
Microbiome Research.....	20
Musculoskeletal Health .....	20
Rare Diseases .....	20
Research Support .....	21
Small Business Development .....	21
Substance Use Disorder .....	21
Therapeutics.....	22
Women's Health.....	23

### Recurring Opportunities

Advanced Research Projects Agency for Health .....	24
Air Force .....	25
Army.....	25
BARDA .....	27
DARPA .....	27
Defense Threat Reduction Agency .....	28
Department of Energy.....	29
National Science Foundation .....	29
Navy .....	29
Office of the Undersecretary of Defense.....	30
<b>GBG Acronyms.....</b>	<b>31</b>





## GBG Report

Updated Monthly

November 12, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

**November 21, 2024** – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

**Women’s Health: Elections, Policy, Advocacy, and What’s Next:** Join G2G on November 13 at 1 pm EST for insights on women’s health regarding the election results, the likely policy priorities in the new Congress and new Administration, and what we can do to influence the process.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AGING (3)</b>		
1.	Research Infrastructure Development and Utilization for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional) (NIH/NIA/ORWH)  PAR-25-218 (R61/33) PAR-25-219 (R33)	These NOFOs invite applications that propose to develop and support the advanced-stage development and utilization of novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. They aim to encourage biomedical, social, and behavioral research and research training directed toward greater understanding of the aging process and the diseases, special problems, and needs of people as they age.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-218.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-218.html</a> (R61/33) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-219.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-219.html</a> (R33)	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFOs open through 12/2/25
2.	NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) (NIH/NIA)  PAR-25-222	This NOFO invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-222.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-222.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 11/5/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARTIFICIAL INTELLIGENCE &amp; MACHINE LEARNING (1)</b>		
3.	Draft: Performance and Reliability Evaluation for Continuous modifications and uSEability of AI (PRECISE-AI) (ARPA-H)  ARPA-H-SOL-25-113	PRECISE-AI aims to create a suite of self-correction techniques that make it possible to automatically maintain peak model performance of predictive AI components across diverse clinical settings. PRECISE-AI will advance novel approaches to optimally support clinician decision-making and scalably manage the performance of AI Decision Support Tools (AI-DSTs) after their commercial deployment.  <a href="https://sam.gov/opp/509b926524f940969c5483542fbc15e7/view">https://sam.gov/opp/509b926524f940969c5483542fbc15e7/view</a>	Dependent upon proposal and award mechanism	Proposal: 1/15/25
		<b>BIOENGINEERING (1)</b>		
4.	Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) (NIH)  PAR-24-325	This NOFO solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 9/7/27
		<b>BIOMEDICAL RESEARCH (4)</b>		
5.	Ocular Laboratory for Analysis of Biomarkers (OCULAB) (ARPA-H)  ARPA-H-SOL-25-115	The OCULAB program envisions a wearable biomarker measurement system that allows for simultaneous, continuous monitoring of tear biomarkers. Because tears are clear and water-based, they offer a way to measure hormones, vitamins, and proteins with less risk to foul the delicate sensor than blood. Additionally, the OCULAB system aims to provide ultra-precise medication dosing for a personalized treatment via a closed-loop delivery system. The program aims to create a tear-based biomarker measurement system that can be inserted into the tear duct.  <a href="https://sam.gov/opp/8913135538804f3daa09966936ebbb40/view">https://sam.gov/opp/8913135538804f3daa09966936ebbb40/view</a> <a href="https://sam.gov/opp/edbe7aa605444d3286278e6cdoe37e2c/view">https://sam.gov/opp/edbe7aa605444d3286278e6cdoe37e2c/view</a>	Dependent upon proposal and award mechanism	Proposers' Day: 12/12/24 Solution Summary: 1/27/25 Proposal: 4/14/25
6.	Forecast: MTEC Fiscal Year 2025 Multi Topic (MTEC)  MTEC-25-Multi-Topic	Medical capabilities play a critical role in each aspect of the future battlespace and must modernize rapidly to maintain Force readiness and increase soldier lethality. MTEC members will be invited to submit enhanced white papers addressing one of the Focus Areas. Anticipated Focus Areas include: Traumatic Brain Injury; Burn Care; Prophylactic to Prevent Infection in Battlefield Wounds; Pathogen Agnostic Countermeasures; Antivirals; Knowledge Product Solutions for the Prevention of Infection in Traumatic Penetrating Wounds; Pharmacogenetics; Nutrition; Musculoskeletal injury; and Computer Simulation.  <a href="https://sam.gov/opp/9da83ed837af4258bcd8d8b117e37cfe/view">https://sam.gov/opp/9da83ed837af4258bcd8d8b117e37cfe/view</a>	Dependent upon proposal and award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>BIOMEDICAL RESEARCH</b>		
7.	2025 Human Exploration Research Opportunities (HERO) NOFO (NASA)  NNJ25ZSA001N	The research will fall into one or more categories corresponding to HRP's five Elements: Space Radiation, Human Health Countermeasures, Exploration Medical Capability, Human Factors and Behavioral Performance, and Research Operations and Integration. This NOFO covers all aspects of research to provide human health and performance countermeasures, knowledge, technologies, and tools to enable safe, reliable, and productive human space exploration.  <a href="https://tinyurl.com/HERO25NOFO">https://tinyurl.com/HERO25NOFO</a>	Dependent upon proposal and award mechanism	Dependent upon program
8.	Forecast: In Vivo Non-Invasive Optical Approaches for Biological systems (UG3/HU3 Clinical Trial Not Allowed) (NIH Common Fund)  NOT-RM-24-014	The goal of the Advancing Non-Invasive Optical Imaging Approaches for Biological Systems initiative is development of next-generation non-invasive or minimally invasive optical imaging techniques to overcome the problem of light scattering in biological systems resulting in high spatial and temporal resolution optical images at significantly greater depths within biological tissues than is currently possible.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-RM-24-014.html">https://grants.nih.gov/grants/guide/notice-files/NOT-RM-24-014.html</a>	Up to \$1.6 million per year, for up to 3 years	Estimated post date: 12/7/24 Estimated proposal date: 3/7/25
		<b>BLOOD DISORDERS (1)</b>		
9.	Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed) (NIH/NIDDK/NHLBI/NIA)  PAS-25-205	The overall objectives of the SHINE program are to catalyze discoveries in basic molecular and cellular biology that provide new insights into the pathogenesis, prevention, detection, and potential treatment of nonmalignant hematologic diseases; to attract new investigators into basic and translational hematology research; to promote productive interdisciplinary research collaborations; and to reinforce a flexible, proactive role for the NIA, NHLBI, and NIDDK to support timely, high impact, leading-edge research by the hematology research community.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAS-25-205.html">https://grants.nih.gov/grants/guide/pa-files/PAS-25-205.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27
		<b>CANCER (31)</b>		
10.	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01/R21 Clinical Trial Not Allowed) (NIH/NCI)  PA-25-121 (R01) PA-25-123 (R21)	These NOFOs promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors and their interplay with established risk factors associated with the development of liver cancer in the United States.  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-25-121.html">https://grants.nih.gov/grants/guide/pa-files/PA-25-121.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PA-25-123.html">https://grants.nih.gov/grants/guide/pa-files/PA-25-123.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 2/5/25 (R01) Proposal: 2/16/25 (R21)



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
11.	Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) (NIH/NCI)  PA-25-172	This NOFO encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science. <a href="https://grants.nih.gov/grants/guide/pa-files/PA-25-172.html">https://grants.nih.gov/grants/guide/pa-files/PA-25-172.html</a>	Up to \$250,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27
12.	Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) (NIH/NCI)  PA-25-253	The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research. <a href="https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html">https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html</a>	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 9/7/28
13.	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) (NIH/NCI)  PAR-24-306	This NOFO encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-306.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-306.html</a>	Up to \$499,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 7/5/26
14.	Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) (NIH/NCI)  PAR-24-311	This NOFO encourages applications focused on developing integrated imaging approaches to investigate the role of inflammation in cancer through strong cross-discipline collaboration between cancer basic science researchers and imaging scientists. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-311.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-311.html</a>	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27
15.	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) (NIH/NCI)  PAR-25-074 (UH2/UH3) PAR-25-075 (UH3)	These NOFOs will accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. They will also support the validation of pharmacodynamic markers and markers of toxicity. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-074.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-074.html</a> (UH2/UH3) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-075.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-075.html</a> (UH3)	Up to \$275,000, for up to 2 years (UH2) Up to \$250,000 per year, for up to 3 years (UH3)	Multiple deadlines; NOFOs open through 10/14/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
16.	NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional) (NIH/NCI)  PAR-25-078	This NOFO supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-078.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-078.html</a>	Up to \$50,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 1/7/26
17.	Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) (NIH/NCI)  PAR-25-079	This NOFO intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-079.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-079.html</a>	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 11/5/26
18.	Co-infection and Cancer (R01/R21 Clinical Trial Not Allowed) (NIH/NCI)  PAR-25-082 (R01) PAR-25-083 (R21)	These NOFOs intend to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-082.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-082.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-083.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-083.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 11/16/25
19.	Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required) (NIH)  PAR-25-098	This NOFO aims to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-098.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-098.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/7/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
20.	Cancer Prevention and Control Clinical Trials Planning Grant Program (U34/R34 Clinical Trials Optional) (NIH/NCI)  PAR-25-103 (U34) PAR-25-104 (R34)	These NOFOs will facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Investigators often lack critical information necessary to finalize the trial protocol completely. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-103.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-103.html</a> (U34) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-104.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-104.html</a> (R34)	Up to \$450,000 for up to 3 years (no CT) Up to \$600,000 for up to 3 years (CT)	Multiple deadlines; NOFOs open through 10/25/27
21.	Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) (NIH/NCI)  PAR-25-106	This NOFO encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address overcoming major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-106.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-106.html</a>	Up to \$475,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 5/4/26
22.	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01/R21 Clinical Trial Not Allowed) (NIH/NCI)  PAR-25-107 (R01) PAR-25-108 (R21)	These NOFOs solicit grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-107.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-107.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-108.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-108.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 2/5/25 (R01) Proposal: 2/16/25 (R21)
23.	Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2/U01 Clinical Trial Not Allowed) (NIH/NCI)  PAR-25-118 (UH2) PAR-25-119 (U01)	It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-118.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-118.html</a> (UH2) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-119.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-119.html</a> (U01)	Up to \$275,000, for up to 2 years (UH2) Up to \$500,000 per year, for up to 5 years (U01)	Multiple deadlines; NOFOs open through 10/23/25





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
24.	The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) (NIH/NCI)  PAR-25-130	The overall goal of the MetNet is to advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and cohesive picture of the processes involved. This NOFO invites applications for MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level approaches to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing research across the Network.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-130.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-130.html</a>	Up to \$500,000 per year, for up to 5 years	Letter of intent: 5/20/25 Proposal: 6/20/25
25.	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) (NIH/NCI)  PAR-25-139	This NOFO intends to support preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-139.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-139.html</a>	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 7/1/25
26.	Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) (NIH/NCI)  PAR-25-145	This NOFO supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, and translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-145.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-145.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27
27.	Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) (NIH/NCI)  PAR-25-153	This NOFO intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html</a>	Dependent upon proposal, for up to 3 years	Multiple deadlines; NOFO open through 7/5/26
28.	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) (NIH/NCI)  PAR-25-175	This NOFO invites applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of these modalities in the characterization of therapy response and/or emergence of treatment resistance.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-175.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-175.html</a>	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 1/7/28



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
29.	Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) (NIH/NCI)  PAR-25-186	The goal of this NOFO is to reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-186.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-186.html</a>	Dependent upon proposal, for up to 5 years	Proposal: 2/28/25
30.	Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) (NIH/NCI)  PAR-25-237	The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings, where appropriate. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-237.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-237.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 11/5/26
31.	Forecast: FY25 Breast Cancer Research Program (BCRP) (DoD/CDMRP)	Five awards are anticipated: Breakthrough Award (includes 4 funding levels and partnering options); Era of Hope Scholar Award; Clinical Research Extension Award; Transformative Breast Cancer Consortium Award; and Transformative Breast Cancer Consortium Development Award. Applications submitted to the FY25 BCRP must address one or more of the <a href="#">overarching challenges</a> . <a href="https://cdmrp.health.mil/pubs/press/2025/25bcrrpreann">https://cdmrp.health.mil/pubs/press/2025/25bcrrpreann</a>	Up to \$15 million Dependent upon proposal and award mechanism	TBD
		<b>CENTRAL NERVOUS SYSTEM (5)</b>		
32.	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) (NIH/NIMH/NIA)  PAR-25-036	This NOFO invites research grant applications that propose the development and evaluation of novel radioligands for PET or SPECT for molecular targets that are implicated in brain disorders as tools to study disease pathophysiology and/or for assessing target engagement of potential therapeutic candidates. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-036.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-036.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 5/7/26
33.	Engineering Next-Generation Human Nervous System Microphysiological Systems (R01/R21 Clinical Trials Not Allowed) (NIH)  PAR-25-198 (R01) PAR-25-199 (R21)	These NOFOs encourage applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in healthy and disease states. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-198.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-198.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-199.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-199.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 1/7/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CENTRAL NERVOUS SYSTEM</b>		
34.	BRAIN Initiative: Next-Generation Devices; and Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional) (NIH)  RFA-NS-25-021 (UG3/UH3) RFA-NS-25-022 (UH3)	These NOFOs aim to encourage investigators to pursue translational activities and small clinical studies; or to pursue first-in-human or early stage clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-021.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-021.html</a> (UG3/UH3) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-022.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-022.html</a> (UH3)	Up to \$500,000 per year, for up to 1 year (UG3) Up to \$1.5 million per year, for up to 5 years (UH3)	Multiple deadlines; NOFOs open through 9/28/26
		<b>COGNITIVE AND BRAIN HEALTH (9)</b>		
35.	Forecast: Coordination Center for the Alzheimer's Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed) Notice Number:NOT-AG-24-077 (NIH/NIA)  NOT-AG-24-077	The ADSP Consortium Coordination Center will lead and manage cross-consortium functions, including effective communication, collaboration, outreach, dissemination, training, and coordination across the components of the ADSP. The overall goal of the ADSP Consortium Coordination Center is to integrate the efforts of all the ADSP projects, and, through innovation, to promote a research environment that facilitates synergy, collaboration, and communication among ADSP investigators. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-077.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-077.html</a>	Up to \$1 million per year	Estimated post date: 11/25/24 Estimated proposal date: 2/14/25
36.	Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) (NIH/NINDS)  PAR-25-024	The purpose of this NOFO is to promote the development of fit-for-purpose candidate biomarkers and composite biomarker that enable more efficient clinical trials advance therapeutic development or clinical practice help guide clinical care decisions. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-024.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-024.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/7/28
37.	NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) (NIH/NINDS)  PAR-25-049	This NOFO encourages applications for multi-center clinical trials focused on neurological emergencies. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-049.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-049.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 3/6/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COGNITIVE AND BRAIN HEALTH</b>		
38.	Translational Neural Devices (R61/R33 - Clinical Trial Optional) (NIH/NINDS)  PAR-25-053	This NOFO intends to encourage investigators to pursue translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-053.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-053.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/28/27
39.	BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional) (NIH)  RFA-MH-26-140	The BRAIN Initiative BBQS funding opportunities broadly support 1) development of tools for simultaneous, multimodal measurement of behavior within complex, dynamic physical and/or social environments and synchronize these data with simultaneously-recorded neural activity and 2) development of novel conceptual and computational models that capture dynamic behavior-environment relationships across multiple timescales and that can integrate correlated neural activity into the model. This NOFO focuses exclusively on the development of novel sensor technology and bioelectronic devices related to the BBQS program. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-140.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-140.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 6/15/27
40.	NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2 - Clinical Trial Not Allowed) (NIH/NINDS)  RFA-NS-25-019	This NOFO aims to support the establishment of programs to enhance research rigor and transparency practices within academic and research institutions to promote a culture of high-quality neuroscience research. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-019.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-019.html</a>	Dependent upon proposal, for up to 3 years	Letter of intent: 9/17/25 Proposal: 10/17/25
41.	Forecast: FY25 Peer Reviewed Alzheimer's Research Program (DoD/CDMRP)	Three awards are anticipated in the PRARP: Transforming Care Award; Transforming Diagnosis Award; and Transforming Research Award. All applications must be relevant to one or more of the <a href="#">priority areas</a> . All FY25 PRARP mechanisms have a Career Initiation or Transition Partnering PI Option (CITPO) to encourage research capacity in this critical area. <a href="https://cdmrp.health.mil/pubs/press/2025/25prarppreann">https://cdmrp.health.mil/pubs/press/2025/25prarppreann</a>	Up to \$1.8 million, for up to 4 years Dependent upon award mechanism	TBD
		<b>COMBAT CASUALTY CARE (1)</b>		
42.	Development of an EXMED mobile Command, Control, Communications, and Computers IT (C4IT) solution (MTEC)  MTEC-25-02-EXMED	The objective of this effort is to develop expeditionary and interoperable information technology to enable health care delivery, medical command and control, medical logistics, and patient movement in austere and contested environments. <a href="https://mtec-sc.org/wp-content/uploads/2024/11/MTEC-25-02-EXMED_Final.pdf">https://mtec-sc.org/wp-content/uploads/2024/11/MTEC-25-02-EXMED_Final.pdf</a>	Up to \$2.693 million, for up to 18 months	Proposal: 11/25/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COMMUNICATION DISORDERS (3)</b>		
43.	NOSI: Autoimmune Inner Ear Disease (Clinical Trials Not Allowed) (NIH/NIDCD/ORWH)  NOT-DC-25-003	The intent of this NOSI is to promote research to better understand autoimmune inner ear disease (AIED); also known as autoimmune-associated sudden sensorineural hearing loss (SSNHL). The overall goal is to identify strategies to prevent and treat this disease.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DC-25-003.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DC-25-003.html</a>	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 10/16/27
44.	Forecast: NIDCD Research Grants for Translating Basic Research into Clinical Practice (R01 Clinical Trial Optional) (NIH/NIDCD)  NOT-DC-25-006	The upcoming NOFO will solicit applications for research to support the translation of peer-reviewed and published basic research findings into clinical applications that improve human health in the NIDCD mission areas.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DC-25-006.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DC-25-006.html</a>	Dependent upon proposal	Estimated post date: 12/18/24 Estimated proposal date: 2/13/25
45.	NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional) (NIH/NIDCD)  PAR-25-120	This NOFO is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-120.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-120.html</a>	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 10/15/27
		<b>COMPLEMENTARY AND INTEGRATIVE HEALTH (4)</b>		
46.	Clinical and Data Coordinating Centers for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3/U24 Clinical Trial Required) (NIH/NCCIH)  PAR-24-275 (UG3/UH3) PAR-24-276 (U24)	These NOFOs encourage applications for investigator-initiated multisite clinical trials to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs, and/or multicomponent interventions that include physical, psychological, and/or nutritional approaches in NCCIH-designated areas of high research priority; as well as for a collaborating data coordinating center.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-275.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-275.html</a> (UG3/UH3) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-276.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-276.html</a> (U24)	Dependent upon proposal, for up to 7 years	Multiple deadlines; NOFOs open through 7/14/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COMPLEMENTARY AND INTEGRATIVE HEALTH</b>		
47.	Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products and Data Coordinating Center (Collaborative UG3/UH3/U24 Clinical Trial Required) (NIH/NCCIH)  PAR-24-312 (UG3/UH3) PAR-24-313 (U24)	These NOFOs encourage applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority; and for a collaborating Data Coordinating Center. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-312.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-312.html</a> (UG3/UH3) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-313.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-313.html</a> (U24)	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 7/14/26
		<b>DENTAL AND CRANIOFACIAL RESEARCH (1)</b>		
48.	NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) (NIH/NIDCR)  PAR-25-057	Studies appropriate for this NOFO are those testing a drug, biologic, device, or procedure to improve dental, oral, or craniofacial diseases or conditions. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-057.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-057.html</a>	Up to \$400,000 per year, for up to 1 year (UG3) Dependent upon proposal, for up to 5 years (UH3)	Multiple deadlines; NOFOs open through 1/6/28
		<b>DIAGNOSTICS (1)</b>		
49.	Forecast: Non-destructive Viral ID (DoD/DARPA)  HR0011SB20254-01	To help mitigate potential exposure risks, DoD entities tasked with force health protection rapidly assess, often on-site, a range of sample types for potential biological threats. This SBIR will address both the significant limitations to rapid, on-site biosurveillance in resource constrained environments and the lab-centric designs for non-destructive pathogen ID by developing human-portable, low size, weight, and power (SWaP) technology to rapidly and non-destructively ID viruses on-site and in the field. <a href="https://www.dodsbirsttr.mil/topics-app/?baa=DOD_SBIR_2025_P1_C4&amp;release=2">https://www.dodsbirsttr.mil/topics-app/?baa=DOD_SBIR_2025_P1_C4&amp;release=2</a>	Up to \$1.2 million, for up to 2 years	Proposal: 1/8/25
		<b>DIVERSITY AND INCLUSION (2)</b>		
50.	Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional) (NIH)  PAR-25-117	The ReWARD Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to DEIA and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-117.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-117.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/7/28



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DIVERSITY AND INCLUSION</b>		
51.	Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) (NIH)  PAS-25-190	This initiative is intended to promote and provide opportunities for new researchers and earlier research independence, and to maintain the careers of at-risk investigators. <a href="https://grants.nih.gov/grants/guide/pa-files/PAS-25-190.html">https://grants.nih.gov/grants/guide/pa-files/PAS-25-190.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27
		<b>ENERGY SCIENCE (2)</b>		
52.	Genomics - Enabled Understanding and Advancing Knowledge on Plant Gene Function(s) (DoE)  DE-FOA-0003452	This NOFO solicits applications to effectively design bioenergy crops by developing approaches to: a) understand regulatory elements, biological mechanisms and develop predictive models for dissecting multigene traits and their component parts that govern plant growth under different growing conditions, biochemical and signaling pathways; b) understand genetic components and molecular mechanisms underlying plant regeneration/organogenesis in tissue culture to improve heterologous DNA transfer to germlines of bioenergy crops; and c) understand genetic and molecular mechanisms that will reduce the cycle time for out-crossing energy crops to speed development of new plant feedstocks underpinning a more broader and more competitive US bioeconomy. <a href="https://science.osti.gov/-/media/grants/pdf/foas/2025/DE-FOA-0003452.pdf">https://science.osti.gov/-/media/grants/pdf/foas/2025/DE-FOA-0003452.pdf</a>	Up to \$3 million, for up to 3 years	Pre-Application: 12/2/24 Proposal: 2/10/25
53.	Environmental System Science (ESS) (DoE)  DE-FOA-0003475	The BER ESS program goal is to advance an integrated, robust, and scale-aware predictive understanding of terrestrial systems and their interdependent microbial, biogeochemical, ecological, hydrological, and physical processes. To support this goal, the program uses a systems approach to develop an integrative framework to elucidate the complex processes and controls on the structure, function, feedbacks, and dynamics of terrestrial and watershed systems, that span from molecular to global scales and extend from the bedrock through the soil, rhizosphere, and vegetation to the atmosphere. The ESS program scope advances foundational process knowledge with an emphasis on understudied ecosystems. <a href="https://science.osti.gov/ber/-/media/grants/pdf/foas/2025/DE-FOA-0003475.pdf">https://science.osti.gov/ber/-/media/grants/pdf/foas/2025/DE-FOA-0003475.pdf</a>	Up to \$1 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 12/11/24 Proposal: 3/13/25
		<b>ENVIRONMENTAL HEALTH (1)</b>		
54.	Environmental Health Disparities Centers (P50) Clinical Trial Optional (NIH)  RFA-MD-24-010	The Environmental Health Disparities Centers program seeks to solicit multidisciplinary research, research capacity building, and community-engaged research activities on environmental health disparities and environmental justice research for populations and communities experiencing health disparities within the US and its territories. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-24-010.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-24-010.html</a>	Up to \$1 million per year, for up to 5 years	Proposal: 12/5/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>GENOMICS (4)</b>		
55.	Forecast: Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional) (NIH/NHGRI)  NOT-HG-25-011	The upcoming NOFO will intended to support early career researchers as they begin to establish a vibrant, independent research program in genomics. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HG-25-011.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HG-25-011.html</a>	Up to \$400,000	Estimated post date: 12/18/24 Estimated proposal date: 2/28/25
56.	In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed) (NIH/NICHD/NIDCR)  PAR-25-140	The purpose of this NOFO is two-fold: 1) to encourage submission of applications to do more in-depth phenotyping on investigator-selected cohorts of embryonic lethal or subviable KO mouse strains generated by the IMPC; and, 2) to encourage submission of applications to use investigator-selected embryonic lethal, perinatal lethal, or subviable IMPC-generated KO mouse strains in hypothesis-driven research focused on placental defects, structural birth defects, and/or fertility issues. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-140.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-140.html</a>	Up to \$499,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 11/5/25
57.	Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) (NIH)  PAR-25-185	The purpose of this initiative is to promote the screening, functional validation and characterization of congenital anomaly-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-185.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-185.html</a>	Up to \$499,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27
58.	Human Brain Single-cell Genomics Explorer (U24 - Clinical Trial Not Allowed) (NIH)  RFA-NS-24-038	The award made via this pilot program will establish an integrated resource that allows users to explore, analyze, and download processed de-identified human brain single-cell transcriptomics and epigenomics data harmonized across reference and disease datasets. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-038.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-038.html</a>	Up to \$1 million per year, for up to 3 years	Letter of intent: 1/14/25 Proposal: 2/14/25
		<b>HEALTH IT &amp; DATA (3)</b>		
59.	Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed) (NIH/NLM)  PAR-25-131	NLM wishes to accelerate access to, and availability of, secure, complete datasets and computational models that can serve as the basis for transformative biomedical discoveries. Innovative at-scale computational approaches that increase the speed and scope of curation processes are needed for data mining and knowledge discovery from growing quantities of biomedical data being produced from ongoing data science advances. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-131.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-131.html</a>	Up to \$250,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 4/15/27





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HEALTH IT &amp; DATA</b>		
60.	Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) (NIH/NLM/NIMH)  PAR-25-235	This NOFO seeks applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-235.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-235.html</a>	Up to \$250,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 7/1/25
61.	Pilot projects to enhance utility and usage of data sets from the Molecular Transducers of Physical Activity Consortium (MoTrPAC) (R03 CT Not allowed) (NIH Common Fund)  RFA-RM-24-011	The purpose of this NOFO is to announce the availability of funding to support novel approaches for analyzing MoTrPAC data, to generate hypotheses and catalyze discoveries; for comparing the publicly released MoTrPAC data to other datasets; and for developing analytic pipelines.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-011.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-011.html</a>	Up to \$50,000, for up to 1 year	Proposal: 12/26/24
		<b>HIV/AIDS (1)</b>		
62.	Targeting Inflammasomes in HIV and Substance Use (R21/R01 Clinical Trial Not Allowed) (NIH/NIDA)  RFA-DA-25-068 (R21) RFA-DA-25-069 (R01)	These NOFOs encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). The overall goal of this program is to facilitate translation of inflammasome research findings into therapeutic tools that improve clinical outcomes in people with HIV.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-068.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-068.html</a> (R21) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-069.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-069.html</a> (R01)	Up to \$275,000, for up to 2 years (R21) Up to \$500,000 per year, for up to 5 years (R01)	Letter of intent: 2/13/25 Proposal: 3/13/25
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE (9)</b>		
63.	Forecast: 2026 NIAID DMID Omnibus Broad Agency Announcement (NIH/NIAID)  HHS-NIH-NIAID-BAA2025-1	This BAA is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases. Research areas include: Development of Candidate Therapeutics, Vaccines, and In Vitro Diagnostics for AMR Bacterial or Fungal Pathogens; and Development of DAA for Viral Families of Pandemic Potential.  <a href="https://sam.gov/opp/f450cc7fee4b4df781f7b8647bf9b943/view">https://sam.gov/opp/f450cc7fee4b4df781f7b8647bf9b943/view</a>	Dependent upon topic area	Estimated post date: 11/22/24
64.	NOSI: Establishing and Utilizing Pre-Clinical Animal Models to Study Post-TB Lung Disease Development (NIH/NIAID)  NOT-AI-24-082	This NOSI will support the establishment and utilization of pre-clinical animal models that strive to (1) better understand the pathophysiology of long-term lung damage resulting from pulmonary TB or (2) better understand the role of the immune response during TB treatment in long-term lung damage.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-082.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-082.html</a>	Up to \$275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOSI open through 1/7/28



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE</b>		
65.	Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21/R01 - Clinical Trial Optional) (NIH)  PAR-25-115 (R21) PAR-25-116 (R01)	These NOFOs aim to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 as well as other chronic illnesses with a potential infectious trigger. Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses are within the scope of this initiative. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-115.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-115.html</a> (R21) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-116.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-116.html</a> (R01)	Up to \$275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 11/16/25
66.	New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-24-068	The purpose of this NOFO is to stimulate the development of new treatments for genital herpes that suppress shedding and lesion formation and reduce transmission. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-068.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-068.html</a>	Up to \$275,000, for up to 2 years (R21) Up to \$300,000 per year, for up to 3 years (R33)	Letter of intent: 12/31/24 Proposal: 1/31/25
67.	Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trials Not Allowed) (NIH/NIAID)  RFA-AI-24-069	The CAPT-CEPs will focus on developing preclinical assays, tools, and models for robust phage therapy research and development (R&D) and advancing phage clinical research. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-069.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-069.html</a>	Up to \$1.2 million per year, for up to 5 years	Letter of intent: 12/28/24 Proposal: 1/28/25
68.	Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) (P01 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-24-074	This NOFO will support multidisciplinary research programs focused on discovery to early development research to inform new approaches to prevent, diagnose, and treat antibiotic-resistant bacterial infections. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-074.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-074.html</a>	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 2/24/25 Proposal: 3/26/25
69.	Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed) (NIH Common Fund)  RFA-RM-24-009	This NOFO solicits applications to develop innovative and novel tools, models, and methods to overcome the major challenges in identifying and characterizing viruses, as well as the development of computational and bioinformatics tools to enhance the analysis of the human virome. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-009.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-009.html</a>	Up to \$350,000 per year, for up to 4 years	Letter of intent: 1/27/25 Proposal: 2/27/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>LYMPHATIC SYSTEM (1)</b>		
70.	Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) (ARPA-H)  ARPA-H-SOL-24-111	The GLIDE program envisions a future where doctors will have a therapeutic armamentarium targeting abnormal lymphatic structure and function, dramatically expanding the role of the lymphatic system, not only for primary lymphatic diseases but in the treatment of all chronic diseases. The program will develop therapeutic and physical interventions that alleviate, repair, and regenerate irregular or dysfunctional lymphatic vasculature, while including product design and commercialization considerations that favor broad accessibility and adoption by the community of hospitals, healthcare providers, and patients.  <a href="https://sam.gov/opp/59f3a67eab7c4747a4b97863874a220e/view">https://sam.gov/opp/59f3a67eab7c4747a4b97863874a220e/view</a>	Dependent upon proposal and award mechanism	Solution Summary: 12/2/24
		<b>MATERNAL AND PEDIATRIC HEALTH (2)</b>		
71.	Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed) (NIH/NICHD)  PAR-25-146	This NOFO aims to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, ‘omics methods, and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-146.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-146.html</a>	Up to \$499,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 6/5/25`
72.	Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional) (NIH/NICHD)  PAR-25-227	This purpose of this NOFO encourages applications that will expand knowledge of the natural history of disorders that currently are, or may become, part of statewide newborn screening programs. A comprehensive understanding of the natural history of a condition is necessary to facilitate appropriate interventions for infants identified by newborn screening.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27
		<b>MEASUREMENT SCIENCE (1)</b>		
73.	Precision Measurement Grant Program (DoC/NIST)  2025-NIST-PMGP-01	The PMGP is seeking applications from eligible applicants for research work in the field of fundamental measurement, testing the basic laws of physics, and/or the determination of fundamental constants, with emphasis on pressing problems or emerging opportunities.  <a href="https://www.grants.gov/search-results-detail/356849">https://www.grants.gov/search-results-detail/356849</a>	Up to \$50,000 per year, for up to 3 years	Pre-Application: 2/3/25 Invited proposal: 3/19/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MEDICAL COUNTERMEASURES (4)</b>		
74.	Forecast: CCRP Initiative: CounterACT Therapeutics Discovery and Early-Stage Development (UG3/UH3 CT Not Allowed) (NIH)  NOT-NS-24-126	The upcoming NOFO will solicit applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-126.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-126.html</a>	Up to \$350,000 per year, for up to 3 years (UG3) Up to \$450,000 per year, for up to 3 years (UH3)	Estimated post date: 3/3/25 Estimated proposal date: 10/17/25
75.	CCRP Initiative: NIH CounterACT Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed) (NIH/NINDS/NIAID)  PAR-25-077	This NOFO invites applications for basic research to inform toxicology of chemical warfare agents and select toxic industrial chemicals and materials that have primary or secondary effects on the nervous system. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-077.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-077.html</a>	Up to \$300,000 per year, for up to 3 years	Multiple deadlines; NOFO open through 10/16/26
76.	CCRP Initiative: NIH CounterACT Translational Exploratory/ Developmental Research Projects (R21 Clinical Trial Not Allowed) (NIH)  PAR-25-114	This NOFO supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-114.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-114.html</a>	Up to \$275,000, for up to 2 years	Letter of intent: 4/30/25 Proposal: 5/30/25
77.	Comparing Animal Models to Organ Tissue Equivalents (CAMO) (MCDC)  RPP-25-02	Well-developed MPS that are capable of being used to test the efficacy of medical countermeasures and provide results that are directly comparable to well-characterized animal model results. The proposed work should leverage systems that have previously shown efficacious results in testing medical countermeasures. <a href="https://www.medcbrn.org/solicitations/">https://www.medcbrn.org/solicitations/</a>	Must be MCDC member to apply	Proposal: 11/25/24
		<b>MENTAL HEALTH (3)</b>		
78.	Laboratories to Optimize Digital Health (R01 Clinical Trial Required) (NIH/NIMH)  PAR-25-136	This NOFO is intended to support the development of digital health test beds that leverage well-established digital health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-136.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-136.html</a>	Dependent upon proposal, for up to 4 years	Multiple deadlines; NOFO open through 11/5/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MENTAL HEALTH</b>		
79.	Pilot Effectiveness and Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) (NIH/NIMH)  PAR-25-206 (R01) PAR-25-207 (R01)	NIMH seeks applications for pilot/research projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-206.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-206.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-207.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-207.html</a> (R01)	Up to \$750,000, for up to 3 years (206) Dependent upon proposal, for up to 5 years (207)	Multiple deadlines; NOFOs open through 11/5/27
		<b>MICROBIOME RESEARCH (2)</b>		
80.	Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional) (NIH)  PAR-25-210 (R33) PAR-25-211 (R61/R33)	These NOFOs support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions. They aim to identify, understand, and develop strategies to address barriers in precision probiotic interventions' development to account for human heterogeneity resulting in inconsistent responses to probiotic treatments.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-210.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-210.html</a> (R33) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-211.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-211.html</a> (R61/R33)	Up to \$350,000 per year, for up to 5 years	Multiple deadlines; NOFOs open through 6/2/27
		<b>MUSCULOSKELETAL HEALTH (1)</b>		
81.	TMD Collaborative for IMproving PATient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional) (NIH)  RFA-DE-25-003	The purpose of TMD IMPACT is to establish a national, interdisciplinary, patient-centered research collaborative that will advance TMD basic and clinical research, research training, and translation to evidence-based treatments and improved clinical care.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-25-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-25-003.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 12/10/24 Proposal: 1/10/25
		<b>RARE DISEASES (2)</b>		
82.	Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ARPA-H)  ARPA-H-MAI-24-01-07	The DECIDE ET endeavors to produce tools and technology that enable accelerated evaluation and validation of GMP for small batch therapies by demonstrating product quality and consistency that is commensurate with the amount of therapy that needs to be produced. By creating quantitative method(s) to dynamically inform the number of required batches, DECIDE seeks to ensure access to critical therapeutic solutions for Americans and provide a revolutionary pathway to address market failures by innovating approaches to right-size cell therapy production for pediatric rare disease.  <a href="https://sam.gov/opp/1be8b530b34841b580f7886392dfd184/view">https://sam.gov/opp/1be8b530b34841b580f7886392dfd184/view</a>	Dependent upon proposal and award mechanism	Proposal: 11/18/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>RARE DISEASES</b>		
83.	Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) (NIH)  PAR-25-122	The goal of this NOFO is to solicit applications for pilot projects to elucidate a role for understudied proteins in rare disease. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-122.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-122.html</a>	Up to \$100,000, for up to 1 year	Multiple deadlines; NOFO open through 11/16/27
		<b>RESEARCH SUPPORT (1)</b>		
84.	Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01 Clinical Trial Not Allowed) (NIH/ORIP)  PAR-25-076	The ORIP encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this NOFO should be hypothesis driven with strong preliminary data. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-076.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-076.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 7/5/25
		<b>SMALL BUSINESS DEVELOPMENT (1)</b>		
85.	FY 2025 NIST Small Business Innovation Research Program Phase I (DoC/NIST)  2025-NIST-SBIR-01	NIST enables the design and manufacture of biological systems for products such as high-value pharmaceuticals and commodity chemicals by developing advanced measurement capabilities from the molecular to the cellular system scale. NIST plays a significant role to promote and protect the U.S. bioeconomy through building next generation measurement science (biometrology) capabilities and engineering biology laboratories for accelerating responsible biotechnology innovations. <a href="https://www.grants.gov/search-results-detail/356882">https://www.grants.gov/search-results-detail/356882</a>	Up to \$100,000, for up to 6 months	Proposal: 12/27/24
		<b>SUBSTANCE USE DISORDER (3)</b>		
86.	Forecast: NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional) (NIH/NIDA)  NOT-DA-24-049	The Racial Equity Visionary Award Program supports independent investigators proposing highly innovative research that 1) challenges scientific paradigms that perpetuate inequities, and 2) lays groundwork for large scale efforts to impact substance use-related disparities that affect racial and/or ethnic minority populations in the United States. Supported projects should have the potential to open new areas of research and produce results that may lead to truly novel approaches to substance use prevention, treatment or recovery. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-049.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-049.html</a>	Up to \$700,000	Estimated post date: 3/1/25 Estimated proposal date: 10/14/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>SUBSTANCE USE DISORDER</b>		
87.	<p>Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44/R41/R42 - Clinical Trials Optional) (NIH/NIDA)</p> <p>RFA-DA-26-018 (R43/R44) RFA-DA-26-019 (R41/R42)</p>	<p>These NOFOs encourage applications to pursue the translation of target-agnostic technologies with sensitivity and selectivity similar to liquid chromatography-mass spectrometry (LC-MS). Applications received in response to this NOFO are expected to address development of such devices with significantly lower initial cost and low cost of operation compared with state of the art.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-018.html</a> (R43/R44) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html</a> (R41/R42)</p>	<p>Up to \$306,872, for up to 1 year (Phase I) Up to \$2,045,816, for up to 2 years (Phase II)</p>	<p>Letter of intent: 1/19/25 Proposal: 2/19/25</p>
		<b>THERAPEUTICS (8)</b>		
88.	<p>Computational ADME Tox AnaLYsis for Safer Therapeutics (CATALYST) Innovative Solutions Opening (ARPA-H)</p> <p>ARPA-H-SOL-24-114</p>	<p>CATALYST invites proposals across three technical areas: data discovery and deep learning methods for drug safety models, living systems tools for model development, and in silico models of human physiology. CATALYST aims to revolutionize preclinical drug safety prediction by developing human-based models that accurately estimate toxicity and safety profiles for drug candidates.</p> <p><a href="https://sam.gov/opp/325e7a5a97124b6b9b4916818e88cb91/view">https://sam.gov/opp/325e7a5a97124b6b9b4916818e88cb91/view</a></p>	<p>Dependent upon proposal and award mechanism</p>	<p>Solution Summary: 11/25/24 Proposal: 1/31/25</p>
89.	<p>Forecast: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (R41/R42/R43/R44 Clinical Trial Optional) (NIH/NIAAA)</p> <p>NOT-AA-24-014 (R41/R42) NOT-AA-24-015 (R43/R44)</p>	<p>These NOFOs seek applications that propose to advance the following classes of therapeutics beyond pre-clinical development by preparing to seek regulatory approval for future trials: small molecules, natural products, and biologics, which broadly include peptides, proteins, oligonucleotides, gene therapies, and cell therapies.</p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-014.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-014.html</a> (R41/R42) <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-015.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-015.html</a> (R43/R44)</p>	<p>Up to \$1 million per year, for up to 2 years (Phase I) Up to \$2 million per year, for up to 3 years (Phase II)</p>	<p>Estimated post date: 1/16/25 Estimated proposal date: 4/5/25</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>THERAPEUTICS</b>		
90.	IGNITE: Assay Development and Neurotherapeutic Agent Identification; Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery; and Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) (NIH/NINDS)  PAR-25-059 PAR-25-060 PAR-25-225`	These NOFOs encourage: research to develop in vitro, ex vivo or in vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders; the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder; pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-059.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-059.html</a> <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-060.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-060.html</a> <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html</a>	Up to \$750,000, for up to 3 years	Multiple deadlines; NOFOs open through 10/20/27
91.	Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed) (NIH/NIMH)  PAR-25-063	The overarching goal of this NOFO is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-063.html">https://grants.nih.gov/grants/guide/pa-files/PAR-25-063.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 5/7/26
92.	Facilitating T1 Translational Aging Research: Preclinical and Early Phase Human Studies (UG3/UH3 Clinical Trial Optional) (NIH/NIA)  RFA-AG-25-027	This NOFO invites applications on T1 translational aging research which focus on advancing new therapeutics from preclinical stages to FIH trials for aging-related conditions, such as sarcopenia, heart failure with preserved ejection fraction (HFpEF), and deficits such as immunosenescence. This NOFO supports the following two categories of milestone-driven projects: Traditional de novo drug development and Data-driven computational drug repurposing strategies.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-027.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-027.html</a>	Up to \$350,000 per year, for up to 2 years (UG3) Up to \$700,000 per year, for up to 3 years (UH3)	Letter of intent: 12/10/24 Proposal: 1/10/25
		<b>WOMEN'S HEALTH (1)</b>		
93.	Action for Women's Health (Pivotal)	Action for Women's Health is a \$250 million global open call launched by Pivotal that will fund organizations around the world that are improving women's mental and physical health. Eligible organizations serve women and have a record of improving women's mental or physical health. They should center equity in their approach and be poised to scale their work to strengthen the health of more women. Nonprofits only.  <a href="https://womenshealth.leverforchange.org/submit">https://womenshealth.leverforchange.org/submit</a>	Up to \$5 million	Registration: 12/3/24 Proposal: 1/10/25







# Recurring Opportunities

November 12, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)</b>		
94.	Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO)  ARPA-H-SOL-24-103	RSO seeks solution summaries and proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. The following interest areas categorize the ground-breaking research we seek to support: Sociotechnical System Innovation; Health Ecosystem Integration; and Adaptive & Antifragile Solutions.  <a href="https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view">https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view</a>	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
95.	Office-Wide Innovative Solutions Opening for Health Science Futures (HSF)  ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems.  <a href="https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view">https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view</a>	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
96.	Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO)  ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Scalable Technologies and Interventions; Collaborative Distribution Networks; and Biomanufacturing Innovations.  <a href="https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view">https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view</a>	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
97.	Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO)  ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes.  <a href="https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view">https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view</a>	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AIR FORCE (3)</b>		
98.	Airman Readiness Medical Research (ARMR) Hybrid BAA  FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. <a href="https://www.grants.gov/search-results-detail/327332">https://www.grants.gov/search-results-detail/327332</a>	Up to \$49 million, per award	White papers accepted on rolling basis until 5/1/25
99.	Research Interests of the Air Force Office of Scientific Research  FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). <a href="https://www.grants.gov/search-results-detail/345653">https://www.grants.gov/search-results-detail/345653</a>	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
100.	Research Interests of the United States Air Force Academy  USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. <a href="https://www.grants.gov/search-results-detail/330175">https://www.grants.gov/search-results-detail/330175</a>	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		<b>ARMY (8)</b>		
101.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA)  BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. <a href="https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view">https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view</a>	Dependent upon proposal	Preproposals accepted through 2/7/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY</b>		
102.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB  CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems.  <a href="https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view">https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
103.	USAMRDC Broad Agency Announcement for Extramural Medical Research  HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine.  <a href="https://www.grants.gov/search-results-detail/343725">https://www.grants.gov/search-results-detail/343725</a>	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
104.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development  HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments.  <a href="https://www.grants.gov/search-results-detail/349586">https://www.grants.gov/search-results-detail/349586</a>	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
105.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research  W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: <a href="https://www.arl.army.mil/opportunities/arl-baa/">https://www.arl.army.mil/opportunities/arl-baa/</a> <a href="https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view">https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
106.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research  W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.  <a href="https://sam.gov/opp/ee8d9ecec4f94269b6e1ac16b09d9417/view">https://sam.gov/opp/ee8d9ecec4f94269b6e1ac16b09d9417/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY</b>		
107.	Army Applications Lab BAA for Disruptive Applications <a href="#">W911NF-24-S-0008</a>	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. <a href="https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view">https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view</a>	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
108.	Army Combat Capabilities Development Command Broad Agency Announcement <a href="#">W911QY20R0022</a>	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. <a href="https://www.grants.gov/search-results-detail/327285">https://www.grants.gov/search-results-detail/327285</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		<b>BARDA (2)</b>		
109.	BARDA Broad Agency Announcement <a href="#">BAA-23-100-SOL-00004</a>	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). <a href="https://sam.gov/opp/764c53aa6dac43538ef902a2bc2af44f/view">https://sam.gov/opp/764c53aa6dac43538ef902a2bc2af44f/view</a>	Dependent upon proposal	Proposal: 9/25/28
110.	BARDA DRIVe EZ-BAA <a href="#">DRIVeEZBAA22100SOL00003</a>	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #19: Healing Lungs; AOI #24: RePAIR; AOI #28: Influenza Vaccine Innovation. <a href="https://sam.gov/opp/1af712dc77c347e2841eff3bb91f6331/view">https://sam.gov/opp/1af712dc77c347e2841eff3bb91f6331/view</a>	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<b>DARPA (2)</b>		
111.	Biological Technologies BAA <a href="#">HR001124S0034</a>	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. <a href="https://sam.gov/opp/5fff3c4c76c341a4a6b1d2010211c793/view">https://sam.gov/opp/5fff3c4c76c341a4a6b1d2010211c793/view</a>	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/10/25
112.	Defense Sciences Office, Office-wide <a href="#">HR001124S0039</a>	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. <a href="https://sam.gov/opp/3c1dea286b74897bed07f3eefb446a0/view">https://sam.gov/opp/3c1dea286b74897bed07f3eefb446a0/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DEFENSE THREAT REDUCTION AGENCY (4)</b>		
113.	Research and Development Innovations Broad Agency Announcement  HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at <a href="https://www.dtra.mil/">https://www.dtra.mil/</a> ): <ul style="list-style-type: none"> <li>• Understand current and emerging WMD situations, threats, and capabilities</li> <li>• Enable effective and integrated WMD deterrence</li> <li>• Control, disable, and defeat current and emerging WMD threats</li> <li>• Protect the force and mitigate crises from WMD</li> <li>• Enable cross-cutting capabilities</li> </ul> <a href="https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view">https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view</a>	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
114.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA)  HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures.  <a href="https://www.grants.gov/search-results-detail/353860">https://www.grants.gov/search-results-detail/353860</a>	Dependent upon proposal and award mechanism	Proposal: 4/28/29
115.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement  HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness.  <a href="https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view">https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view</a>	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
116.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD)  HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration.  <a href="https://www.grants.gov/search-results-detail/356612">https://www.grants.gov/search-results-detail/356612</a>	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DEPARTMENT OF ENERGY (1)</b>		
117.	FY 2025 Continuation of Solicitation for the Office of Science Financial Assistance Program  DE-FOA-0003432	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. <a href="https://www.grants.gov/search-results-detail/356590">https://www.grants.gov/search-results-detail/356590</a>	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/25
		<b>NATIONAL SCIENCE FOUNDATION (2)</b>		
118.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I)  NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the <a href="#">NSF SBIR program topics</a> support the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required <a href="#">Project Pitch</a> allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. <a href="https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-0/nsf24-579/solicitation">https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-0/nsf24-579/solicitation</a>	Up to \$275,000 for up to 1 year	<a href="#">Project pitches</a> accepted on a rolling basis through 3/5/25.
119.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track)  NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. <a href="https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation">https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation</a>	Up to \$1,555,000, for up to 3 years	<a href="#">Project pitches</a> accepted on a rolling basis through 11/5/25. Proposal: 3/5/25
		<b>NAVY (3)</b>		
120.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology  N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. <a href="https://www.onr.navy.mil/work-with-us/funding-opportunities/fy25-long-range-broad-agency-announcement-baa-navy-and-marine">https://www.onr.navy.mil/work-with-us/funding-opportunities/fy25-long-range-broad-agency-announcement-baa-navy-and-marine</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>NAVY</b>		
121.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research  N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. <a href="https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8bob76b/view">https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8bob76b/view</a>	Dependent upon proposal and award mechanism	White papers accepted through 12/31/24
122.	FY24 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies  N3943024S2000	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. <a href="https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view">https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/7/25
		<b>OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)</b>		
123.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM)  HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. <a href="https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view">https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view</a>	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27





### Terms

**AD/ADRD:** Alzheimer's Disease / Alzheimer's Disease Related Dementias

**Aoi:** Area of Interest

**BAA:** Broad Agency Announcement

**BBB:** Blood-Brain Barrier

**CNS:** Central Nervous System

**FOA:** Funding Opportunity Announcement

**IC:** NIH Institutes and Centers

**NOFO:** Notice of Funding Opportunity

**NOSI:** Notice of Special Interest

**PI:** Principal Investigator

**PTSD:** Post-Traumatic Stress Disorder

**RFI:** Request for Information

**RFP:** Request for Proposal

**SBIR:** Small Business Innovation Research

**SDOH:** Social Determinants of Health

**STTR:** Small Business Technology Transfer

**SUD:** Substance Use Disorder

**TRL:** Technology Readiness Level

**VCID:** Vascular Contributions to Cognitive Impairment and Dementia

### Agencies

**ARPA-H:** Advanced Research Projects Agency for Health

**ASPR:** Administration for Strategic Preparedness and Response

**BARDA:** Biomedical Advanced Research and Development Authority

**CDC:** Centers for Disease Control and Prevention

**CDMRP:** Congressionally Directed Medical Research Programs

**DARPA:** Defense Advanced Research Projects Agency

**DHA:** Defense Health Agency

**DoD:** Department of Defense

**FDA:** U.S. Food and Drug Administration

**MTEC:** Medical Technology Enterprise Consortium

**NIH:** National Institutes of Health

[Back to Table of Contents](#)

## GBG Acronyms

*Updated Monthly*

November 12, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

**NSF:** National Science Foundation

**PCORI:** Patient-Centered Outcomes Research Institute

**USAMRDC:** U.S. Army Medical Research and Development Command

**USAMRIID:** U.S. Army Medical Research Institute of Infectious Diseases

**USSOCOM:** United States Special Operations Command

### NIH Institutes and Centers

**CC:** NIH Clinical Center

**CIT:** NIH Center for Information Technology

**CSR:** NIH Center for Scientific Review

**FIC:** Fogarty International Center

**NCATS:** National Center for Advancing Translational Sciences

**NCCIH:** National Center for Complementary and Integrative Health

**NCI:** National Cancer Institute

**NEI:** National Eye Institute

**NHGRI:** National Human Genome Research Institute

**NHLBI:** National Heart, Lung, and Blood Institute

**NIA:** National Institute on Aging

**NIAAA:** National Institute on Alcohol Abuse and Alcoholism

**NIAID:** National Institute of Allergy and Infectious Diseases

**NIAMS:** National Institute of Arthritis & Musculoskeletal & Skin Diseases

**NIBIB:** National Institute of Biomedical Imaging and Bioengineering

**NICHD:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**NIDA:** National Institute on Drug Abuse

**NIDCD:** National Institute on Deafness and Other Communication Disorders

**NIDCR:** National Institute of Dental and Craniofacial Research

**NIDDK:** National Institute of Diabetes and Digestive and Kidney Diseases

**NIEHS:** National Institute of Environmental Health Sciences

**NIGMS:** National Institute of General Medical Sciences

**NIMH:** National Institute of Mental Health

**NIMHD:** National Institute on Minority Health and Health Disparities

**NINDS:** National Institute of Neurological Disorders and Stroke

**NINR:** National Institute of Nursing Research

**NLM:** National Library of Medicine

